Chinese guidelines related to novel coronavirus pneumonia
T Qiu, S Liang, M Dabbous, Y Wang, R Han… - Journal of market access …, 2020 - mdpi.com
Background and Objective: China has managed to control the coronavirus disease (COVID-19)
with confinement measurements and treatment strategies, while other countries are …
with confinement measurements and treatment strategies, while other countries are …
The impact of COVID-19 on the cell and gene therapies industry: Disruptions, opportunities, and future prospects
T Qiu, Y Wang, S Liang, R Han, M Toumi - Drug discovery today, 2021 - Elsevier
Coronavirus 2019 (COVID-19) has caused significant disruption to the cell and gene therapy
(CGT) industry, which has historically faced substantial complexities in supply of materials, …
(CGT) industry, which has historically faced substantial complexities in supply of materials, …
Challenges in the market access of regenerative medicines, and implications for manufacturers and decision-makers: a systematic review
T Qiu, M Pochopień, E Hanna, S Liang… - Regenerative …, 2022 - Future Medicine
Aim: Regenerative medicines (RMs) are expected to transform the treatment paradigm of
rare, life-threatening diseases, while substantial challenges impede its market access. This …
rare, life-threatening diseases, while substantial challenges impede its market access. This …
[HTML][HTML] Gene therapy evidence generation and economic analysis: pragmatic considerations to facilitate fit-for-purpose health technology assessment
T Qiu, M Pochopien, S Liang, G Saal… - Frontiers in Public …, 2022 - frontiersin.org
Gene therapies (GTs) are considered to be a paradigm-shifting class of treatments with the
potential to treat previously incurable diseases or those with significant unmet treatment …
potential to treat previously incurable diseases or those with significant unmet treatment …
Current state of developing advanced therapies for rare diseases in the European Union
…, M Dabbous, E Hanna, R Han, S Liang… - Expert Opinion on …, 2020 - Taylor & Francis
Objective Advanced Therapy Medicinal Products (ATMPs) present significant therapeutic
advantages for inherited rare diseases. However, the development of orphan ATMPs is …
advantages for inherited rare diseases. However, the development of orphan ATMPs is …
[HTML][HTML] Reinforcing collaboration and harmonization to unlock the potentials of advanced therapy medical products: future efforts are awaited from manufacturers and …
T Qiu, S Liang, Y Wang, C Dussart, B Borissov… - Frontiers in Public …, 2021 - frontiersin.org
Some advanced therapy medicinal products (ATMPs) hold great promises for life-threatening
diseases with high unmet needs. However, ATMPs are also associated with significant …
diseases with high unmet needs. However, ATMPs are also associated with significant …
[HTML][HTML] Low-profile flexible UHF RFID tag design for wristbands applications
GL Huang, CYD Sim, SY Liang, WS Liao… - … and Mobile Computing, 2018 - hindawi.com
In this study, a low-profile ultrahigh frequency (UHF) radio-frequency identification (RFID)
tag antenna designed for wristbands in healthcare applications is proposed. The radiator is …
tag antenna designed for wristbands in healthcare applications is proposed. The radiator is …
Partnership agreements for regenerative medicines: a database analysis and implications for future innovation
T Qiu, Y Wang, S Liang, R Han, M Toumi - Regenerative Medicine, 2021 - Future Medicine
Aim: Partnerships have been leveraged to advance the regenerative medicines (RMs)
development. This study analyzed the evolution of partnership landscape for regenerative …
development. This study analyzed the evolution of partnership landscape for regenerative …
An Overview of Cell and Gene Therapy Development in China
Y Wang, T Qiu, S Liang, M Toumi - Human Gene Therapy, 2022 - liebertpub.com
China, the first country worldwide to approve a gene therapy in 2003, almost lost the advantage
for a head start in cell and gene therapy (CGT) development due to a lack of clear and …
for a head start in cell and gene therapy (CGT) development due to a lack of clear and …
Rapid systematic review on clinical evidence of chloroquine and hydroxychloroquine in COVID-19: critical assessment and recommendation for future clinical trials
Y Wang, S Liang, T Qiu, R Han, M Dabbous… - medrxiv, 2020 - medrxiv.org
Purpose This study aims to critically assess the published studies of Chloroquine (CQ) and
hydroxychloroquine (HCQ) for the treatment of COVID-19 and provide recommendations for …
hydroxychloroquine (HCQ) for the treatment of COVID-19 and provide recommendations for …